AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36729923 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking for 60 min at 60% of peak oxygen uptake
Number of subjects: 54
Study 36729923 — intervention group
Group type: COMPARATOR
Intervention: Resting (Control)
Number of subjects: 54
Study 36729947 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout measured using the Maslach Burnout Inventory-Human Service Survey
Number of subjects: 6331
Study 36729947 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 exposure parameters, specifically redeployment outside normal professional boundaries
Number of subjects: 6331
Study 36729947 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher perceived institutional support
Number of subjects: 6331
Study 36729947 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resilience
Number of subjects: 6331
Study 36730056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilavonemab 300 mg
Number of subjects: 453
Study 36730056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilavonemab 1000 mg
Number of subjects: 453
Study 36730056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilavonemab 2000 mg
Number of subjects: 453
Study 36730056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453
Study 36730070 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine administration
Number of subjects: 64
Study 36730070 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 64
Study 36730114 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-BD
Number of subjects: 145
Study 36730114 — intervention group
Group type: COMPARATOR
Intervention: ERCP
Number of subjects: 145
Study 36730145 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose TPF (Docetaxel 75 mg/m2, Platinum 75 mg/m2, 5-Fluorouracil 750 mg/m2 IVCI x 5 days) followed by weekly cisplatin (40 mg/m2) or carboplatin (AUC 1.5) concurrent with radiation therapy of 70 Gy over 6.5-7 weeks.
Number of subjects: 26
Study 36730145 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose TPF followed by concurrent chemoradiation.
Number of subjects: 26
Study 36730189 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 2
Study 36730189 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoxygenation
Number of subjects: 2
Study 36730189 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 2
Study 36730240 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg/kg/day rifampin for 60 days
Number of subjects: 1359
Study 36730240 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg/kg/day rifampin for 60 days
Number of subjects: 1359
Study 36730240 — intervention group
Group type: COMPARATOR
Intervention: 10mg/kg/day rifampin for 120 days (control)
Number of subjects: 1359
Study 36730289 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of AZA or 6-MP
Number of subjects: 26
Study 36730289 — intervention group
Group type: COMPARATOR
Intervention: Evening dosing of AZA or 6-MP
Number of subjects: 26
Study 36730371 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-graded intraoperative factors
Number of subjects: 65
Study 36730371 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable graft configuration (wrinkled, tight scroll, taco-shaped)
Number of subjects: 65
Study 36730371 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-bubble size smaller than graft diameter
Number of subjects: 65
Study 36730371 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger gas-bubble size
Number of subjects: 65
Study 36730371 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected distance visual acuity
Number of subjects: 65
Study 36730371 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial cell density
Number of subjects: 65
Study 36730749 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine Extended-Release Oral Suspension
Number of subjects: 0
Study 36730749 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36730762 — intervention group
Group type: EXPERIMENTAL
Intervention: Triggered escalating real-time adherence intervention
Number of subjects: 85
Study 36730762 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 85
Study 36730769 — intervention group
Group type: EXPERIMENTAL
Intervention: THC cutoff levels in blood and saliva
Number of subjects: 0
Study 36730797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic incentivization (loss-based and streak)
Number of subjects: 30
Study 36730797 — intervention group
Group type: COMPARATOR
Intervention: Flat-rate incentivization (monetary and electronic device)
Number of subjects: 30
Study 36730797 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA data
Number of subjects: 30
Study 36730797 — intervention group
Group type: COMPARATOR
Intervention: Clinical visits
Number of subjects: 30
Study 36730884 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCOTHROMB score
Number of subjects: 627
Study 36730884 — intervention group
Group type: COMPARATOR
Intervention: Khorana score
Number of subjects: 627
Study 36730946 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided PRK with the STAR S4 IR Excimer Laser System
Number of subjects: 167
Study 36731003 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (2.5-5 mg BID)
Number of subjects: 74
Study 36731003 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban (20 mg QD)
Number of subjects: 74
Study 36731068 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD implantation
Number of subjects: 300
Study 36731072 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 16
Study 36731072 — intervention group
Group type: COMPARATOR
Intervention: Multidetector computed tomography (MDCT)
Number of subjects: 16
Study 36731199 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Nidra
Number of subjects: 22
Study 36731199 — intervention group
Group type: COMPARATOR
Intervention: Control (no Yoga Nidra)
Number of subjects: 22
Study 36731493 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-Centered Information for Parents
Number of subjects: 0
Study 36731493 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36731578 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day discharge (SDD) after ESD
Number of subjects: 831
Study 36731578 — intervention group
Group type: COMPARATOR
Intervention: Admission after ESD
Number of subjects: 831
Study 36731578 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with admission
Number of subjects: 831
Study 36731585 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar 4 mg
Number of subjects: 221
Study 36731588 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) treatment
Number of subjects: 117
Study 36731604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular imaging
Number of subjects: 0
Study 36731865 — intervention group
Group type: EXPERIMENTAL
Intervention: Early angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) therapy initiated within 24 hours of admission.
Number of subjects: 7204
Study 36732038 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 1358
Study 36732049 — intervention group
Group type: EXPERIMENTAL
Intervention: Efmarodocokin alfa (30-90 µg/kg doses given once every 2 weeks or monthly for 12 weeks)
Number of subjects: 56
Study 36732049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 36732164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S 5 × 10^10 viral particles
Number of subjects: 250
Study 36732164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 36732571 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal almond load (20 g) before OGTT
Number of subjects: 60
Study 36732571 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal almond load (20 g) before three major meals
Number of subjects: 60
Study 36732571 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 60
Study 36732627 — intervention group
Group type: EXPERIMENTAL
Intervention: Serplulimab (3 mg/kg) plus cisplatin (50 mg/m2)
Number of subjects: 551
Study 36732627 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cisplatin (50 mg/m2)
Number of subjects: 551
Study 36732628 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab 3 mg/kg plus nivolumab
Number of subjects: 30
Study 36732628 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical absence of circulating tumor DNA (ctDNA) in urine and plasma
Number of subjects: 30
Study 36732694 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs) completed at the start and every 6 months for 1 year, with healthcare provider prompted to view scores.
Number of subjects: 0
Study 36732694 — intervention group
Group type: COMPARATOR
Intervention: Patient-reported outcome measures (PROMs) completed at the start and again after 12 months, with neurologist not able to view scores.
Number of subjects: 0
Study 36732734 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring program (I-FILE) including home spirometry, pulse oximetry, and patient-reported outcomes (PROMs) for two years.
Number of subjects: 700
Study 36732734 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily home spirometry and pulse oximetry in the first three months, followed by once weekly measurements for two years.
Number of subjects: 700
Study 36732788 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based physical activity intervention (12 weeks)
Number of subjects: 146
Study 36732788 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 146
Study 36732823 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Pilates Group (OPG)
Number of subjects: 58
Study 36732823 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-Face Pilates Group (FPG)
Number of subjects: 58
Study 36732823 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 58
Study 36732830 — intervention group
Group type: EXPERIMENTAL
Intervention: Reloading of P2Y12 receptor inhibitors
Number of subjects: 4790
Study 36732920 — intervention group
Group type: EXPERIMENTAL
Intervention: Irisin levels in diabetic patients with CAD
Number of subjects: 100
Study 36732920 — intervention group
Group type: COMPARATOR
Intervention: Irisin levels in diabetic patients without CAD
Number of subjects: 100
Study 36732920 — intervention group
Group type: EXPERIMENTAL
Intervention: Irisin levels as a predictor
Number of subjects: 100
Study 36733279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness levels during COVID-19
Number of subjects: 0
Study 36733279 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index during COVID-19
Number of subjects: 0
Study 36733374 — intervention group
Group type: EXPERIMENTAL
Intervention: SDI-118, a novel procognitive SV2A modulator
Number of subjects: 0
Study 36733374 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36733413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative intravenous injection of butorphanol
Number of subjects: 100
Study 36733413 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 100
Study 36733480 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent mechanical bacterial lysate (PMBL) therapy
Number of subjects: 50
Study 36733480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 36733480 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 36733485 — intervention group
Group type: COMPARATOR
Intervention: Toripalimab plus lenvatinib without radiotherapy (NRT)
Number of subjects: 88
Study 36733485 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus lenvatinib with radiotherapy (RT)
Number of subjects: 88
Study 36734040 — intervention group
Group type: EXPERIMENTAL
Intervention: COBMINDEX
Number of subjects: 142
Study 36734040 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 142
Study 36734148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 30 mg
Number of subjects: 0
Study 36734148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 45 mg
Number of subjects: 0
Study 36734148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36734154 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical breast cancer screening with potential harms and no reduction in mortality
Number of subjects: 751
Study 36734154 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of the presented information
Number of subjects: 751
Study 36734154 — intervention group
Group type: EXPERIMENTAL
Intervention: Disbelief in the screening information
Number of subjects: 751
Study 36734173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ato-Trazo (atomoxetine plus trazodone)
Number of subjects: 15
Study 36734173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant
Number of subjects: 15
Study 36734173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 36734235 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT using cilostazol and either aspirin or clopidogrel (464 patients)
Number of subjects: 925
Study 36734235 — intervention group
Group type: COMPARATOR
Intervention: SAPT using aspirin or clopidogrel alone (461 patients)
Number of subjects: 925
Study 36734235 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT using cilostazol
Number of subjects: 925
Study 36734235 — intervention group
Group type: COMPARATOR
Intervention: SAPT using aspirin or clopidogrel
Number of subjects: 925
Study 36734294 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) combined with low-dose apatinib (500 mg daily)
Number of subjects: 16
Study 36734316 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors during at-home visit
Number of subjects: 20
Study 36734316 — intervention group
Group type: COMPARATOR
Intervention: Wearable sensors during laboratory visit
Number of subjects: 20
Study 36734316 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home visit experience
Number of subjects: 20
Study 36734349 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR
Number of subjects: 908
Study 36734349 — intervention group
Group type: COMPARATOR
Intervention: FFR
Number of subjects: 908
Study 36734351 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based structural heart interventions (left atrial appendage closure and percutaneous mitral valve repair)
Number of subjects: 47
Study 36734354 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.5 pmol/kg per minute) with 0.9% NaCl infusion (750 mL/h)
Number of subjects: 10
Study 36734354 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 0.9% NaCl infusion (750 mL/h)
Number of subjects: 10
Study 36734415 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord blood (UCB) therapy, infused once intravenously
Number of subjects: 13
Study 36734415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley Scale of Infant Development-II (BSID-II)
Number of subjects: 13
Study 36734415 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 13
Study 36734509 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 24861
Study 36734654 — intervention group
Group type: EXPERIMENTAL
Intervention: PTNS with PFE
Number of subjects: 84
Study 36734654 — intervention group
Group type: COMPARATOR
Intervention: Sham PTNS with PFE
Number of subjects: 84
Study 36734848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol-enhanced MRI before treatment with liposomal irinotecan (nal-IRI)
Number of subjects: 27
Study 36735048 — intervention group
Group type: EXPERIMENTAL
Intervention: High TILs concentration
Number of subjects: 372
Study 36735057 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 0
Study 36735057 — intervention group
Group type: COMPARATOR
Intervention: Risdiplam (after initial placebo)
Number of subjects: 0
Study 36735117 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole, everolimus, and carotuximab (letrozole 2.5 mg PO daily, everolimus 10 mg PO daily, carotuximab 15 mg/kg IV every 2 weeks)
Number of subjects: 15
Study 36735143 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan A (n=886)
Number of subjects: 1770
Study 36735143 — intervention group
Group type: COMPARATOR
Intervention: Control video (n=884)
Number of subjects: 1770
Study 36735261 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching every 2 weeks for 6 months with home blood pressure monitoring.
Number of subjects: 316
Study 36735261 — intervention group
Group type: COMPARATOR
Intervention: Usual care for hypertension.
Number of subjects: 316
Study 36735263 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial ICD
Number of subjects: 122
Study 36735263 — intervention group
Group type: COMPARATOR
Intervention: Transvenous ICD
Number of subjects: 122
Study 36735287 — intervention group
Group type: EXPERIMENTAL
Intervention: ItFits-toolkit
Number of subjects: 456
Study 36735287 — intervention group
Group type: COMPARATOR
Intervention: Implementation-as-usual (IAU)
Number of subjects: 456
Study 36735296 — intervention group
Group type: EXPERIMENTAL
Intervention: BeT intervention (peer-led digital intervention over 3 months)
Number of subjects: 150
Study 36735394 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT-III questionnaire
Number of subjects: 84
Study 36735394 — intervention group
Group type: COMPARATOR
Intervention: PedsQL
Number of subjects: 84
Study 36735422 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Incision Sling (SIS)
Number of subjects: 168
Study 36735422 — intervention group
Group type: COMPARATOR
Intervention: Midurethral Sling (TOT)
Number of subjects: 168
Study 36735426 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 40
Study 36735488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rintodestrant
Number of subjects: 16
Study 36735603 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36735635 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative preparation-themed storybook (Elif Has Surgery) read by mother for 10 minutes
Number of subjects: 80
Study 36735635 — intervention group
Group type: COMPARATOR
Intervention: Clinical routine (control group)
Number of subjects: 80
Study 36735665 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal communication (IPC)
Number of subjects: 2792
Study 36735665 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated service outlets (DSO)
Number of subjects: 2792
Study 36735665 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IPC + DSO
Number of subjects: 2792
Study 36735665 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 2792
Study 36735745 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3772847 (10 mg/kg) administered intravenously at Weeks 0, 4, and 8
Number of subjects: 17
Study 36735745 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously at Weeks 0, 4, and 8
Number of subjects: 17
Study 36735745 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3772847 (10 mg/kg)
Number of subjects: 17
Study 36735745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 36735893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 0
Study 36735893 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 0
Study 36735896 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg once every 3 weeks and apatinib 250 mg once per day
Number of subjects: 58
Study 36735911 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIIFc (efmoroctocog alfa) 200 IU/kg per day until tolerization or maximum of 48 weeks
Number of subjects: 16
Study 36735931 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Solution
Number of subjects: 0
Study 36735931 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 36735933 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Digital Care Program (DCP) for MSK pain management
Number of subjects: 9992
Study 36735937 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) system with variable-loop circular catheter, at least 12 applications per vein; adenosine/isoproterenol administered to confirm entrance block.
Number of subjects: 226
Study 36735937 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) system with variable-loop circular catheter.
Number of subjects: 226
Study 36736112 — intervention group
Group type: EXPERIMENTAL
Intervention: Jitongning Tablet (JTNT)
Number of subjects: 0
Study 36736112 — intervention group
Group type: EXPERIMENTAL
Intervention: JTN fractions (JTN-2 and JTN-4)
Number of subjects: 0
Study 36736209 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 0.6 μg/kg over 10 min, followed by continuous infusion of 0.5 μg/kg/h until 1 h before end of surgery)
Number of subjects: 619
Study 36736209 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 619
Study 36736209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study 36736339 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased adalimumab dose intervals to 40 mg every 3 weeks, further to every 4 weeks if in remission at week 24.
Number of subjects: 174
Study 36736339 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing of adalimumab at 40 mg every 2 weeks.
Number of subjects: 174
Study 36736339 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased adalimumab dose intervals (intervention group).
Number of subjects: 174
Study 36736339 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing of adalimumab (control group).
Number of subjects: 174
Study 36736459 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD/CRT-D implanted in NICM patients
Number of subjects: 2429
Study 36736459 — intervention group
Group type: COMPARATOR
Intervention: No ICD/CRT-D implanted in NICM patients
Number of subjects: 2429
Study 36736459 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD/CRT-D implanted in ICM patients
Number of subjects: 2429